amibegron
Small moleculeexperimental
Amibegron (SR-58,611A) was a drug developed by Sanofi-Aventis which acts as a selective agonist for the β3 adrenergic receptor. It is the first orally active β3 agonist developed that is capable of entering the central nervous system, and has antidepressant and anxiolytic effects. — Wikipedia
Clinical trial activity
14 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
14
Phase 3
14
Phase 4
0
Earliest trial started Sep 1, 2003 (NCT00825019)
Timeline
2000s
- Jan 1, 2003
Earliest Phase 3 Sponsor(trial)
Indications
Mechanism of action
- Beta-3 adrenergic receptorAGONIST
ADRB3 agonist
Chemistry & pharmacology
Loading structure…
SMILES
CCOC(=O)COc1ccc2c(c1)C[C@@H](NC[C@H](O)c1cccc(Cl)c1)CC2- Mol. weight
- 403.91 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1193948 ↗
- WikipediaAmibegron ↗
- ChEMBLCHEMBL545437 ↗
Also known as
- acetic acid, ((7-((2-(3-chlorophenyl)-2-hydroxyethyl)amino)-5,6,7,8-tetrahydro-2-naphthalenyl)oxy)-, ethyl ester, hydrochloride, (r-(r*,s*))-
- amibegron
- amibegron
- amibegron
- amibegron
- amibegron
- amibegron hcl
- amibegron hcl
- amibegron hydrochloride
- amibegron hydrochloride
- sr 58611
- sr-58611
- sr-58611
- sr58611a
- sr58611a
- sr 58611a
- sr-58611a
- sr-58611a
- sr-58611a
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00535340 | Phase 3 | Mar 1, 2007 | Sanofi |
| NCT00432614 | Phase 3 | Jan 1, 2007 | Sanofi |
| NCT00397098 | Phase 3 | Nov 1, 2006 | Sanofi |
| NCT00385307 | Phase 3 | Sep 1, 2006 | Sanofi |
| NCT00345098 | Phase 3 | May 1, 2006 | Sanofi |
| NCT00319709 | Phase 3 | Apr 1, 2006 | Sanofi |
| NCT00332891 | Phase 3 | Mar 1, 2006 | Sanofi |
| NCT00266747 | Phase 3 | Dec 1, 2005 | Sanofi |
| NCT00855530 | Phase 3 | Sep 1, 2005 | Sanofi |
| NCT00252343 | Phase 3 | Sep 1, 2005 | Sanofi |
| NCT00252356 | Phase 3 | Sep 1, 2005 | Sanofi |
| NCT00252330 | Phase 3 | Sep 1, 2005 | Sanofi |
| NCT00825058 | Phase 3 | Nov 1, 2003 | Sanofi |
| NCT00825019 | Phase 3 | Sep 1, 2003 | Sanofi |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 14 | 14 | 1 | 2003 |
1 organizations
Page 1 / 1